PFO vs. BBH, NQP, MUA, HRZN, MYN, TYG, KTF, HQL, SOR, and MCI
Should you be buying Flaherty & Crumrine Preferred Income Opportunity Fund stock or one of its competitors? The main competitors of Flaherty & Crumrine Preferred Income Opportunity Fund include VanEck Biotech ETF (BBH), Nuveen Pennsylvania Quality Municipal Income Fund (NQP), BlackRock MuniAssets Fund (MUA), Horizon Technology Finance (HRZN), BlackRock MuniYield New York Quality Fund (MYN), Tortoise Energy Infrastructure (TYG), DWS Municipal Income Trust (KTF), Abrdn Life Sciences Investors (HQL), Source Capital (SOR), and Barings Corporate Investors (MCI). These companies are all part of the "investment offices, not elsewhere classified" industry.
VanEck Biotech ETF (NASDAQ:BBH) and Flaherty & Crumrine Preferred Income Opportunity Fund (NYSE:PFO) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
Given Flaherty & Crumrine Preferred Income Opportunity Fund's higher probable upside, analysts clearly believe VanEck Biotech ETF is more favorable than Flaherty & Crumrine Preferred Income Opportunity Fund.
32.1% of VanEck Biotech ETF shares are owned by institutional investors. Comparatively, 12.9% of Flaherty & Crumrine Preferred Income Opportunity Fund shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
VanEck Biotech ETF received 38 more outperform votes than Flaherty & Crumrine Preferred Income Opportunity Fund when rated by MarketBeat users.
VanEck Biotech ETF pays an annual dividend of $0.71 per share and has a dividend yield of 0.4%. Flaherty & Crumrine Preferred Income Opportunity Fund pays an annual dividend of $0.55 per share and has a dividend yield of 6.6%. Flaherty & Crumrine Preferred Income Opportunity Fund has increased its dividend for 1 consecutive years. Flaherty & Crumrine Preferred Income Opportunity Fund is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
In the previous week, VanEck Biotech ETF had 1 more articles in the media than Flaherty & Crumrine Preferred Income Opportunity Fund. MarketBeat recorded 3 mentions for VanEck Biotech ETF and 2 mentions for Flaherty & Crumrine Preferred Income Opportunity Fund. VanEck Biotech ETF's average media sentiment score of 1.48 beat Flaherty & Crumrine Preferred Income Opportunity Fund's score of 0.92 indicating that Flaherty & Crumrine Preferred Income Opportunity Fund is being referred to more favorably in the news media.
VanEck Biotech ETF has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Flaherty & Crumrine Preferred Income Opportunity Fund has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Summary
VanEck Biotech ETF beats Flaherty & Crumrine Preferred Income Opportunity Fund on 5 of the 9 factors compared between the two stocks.
Get Flaherty & Crumrine Preferred Income Opportunity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flaherty & Crumrine Preferred Income Opportunity Fund Competitors List
Related Companies and Tools
